SureTrader
Home > Boards > US OTC > Biotechs > CYTODYN INC (CYDY)

N =50 is a compromise from statistical significance

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
pearsby09 Member Profile
 
Followed By 9
Posts 2,054
Boards Moderated 1
Alias Born 04/29/16
160x600 placeholder
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 1/10/2018 5:01:36 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/10/2018 4:56:01 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 1/8/2018 4:37:58 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 1/8/2018 4:36:15 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 12/29/2017 5:18:12 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/29/2017 5:13:14 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 12/21/2017 4:30:41 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/21/2017 6:06:16 AM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 12/15/2017 7:37:52 AM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 12/7/2017 4:58:05 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/7/2017 4:53:09 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 12/6/2017 5:25:33 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/6/2017 4:32:06 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) "Edgar (US Regulatory)" - 11/27/2017 4:37:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/27/2017 4:32:49 PM
Tender Offer Statement by Issuer (sc To-i) "Edgar (US Regulatory)" - 11/24/2017 4:28:37 PM
Small Company Offering and Sale of Securities Without Registration (d) "Edgar (US Regulatory)" - 11/16/2017 4:12:12 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/8/2017 4:34:16 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/8/2017 4:34:01 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/2/2017 4:33:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/13/2017 7:20:39 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 10/11/2017 7:53:23 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/11/2017 7:46:31 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 10/10/2017 9:05:18 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/5/2017 2:56:11 PM
pearsby09   Friday, 11/10/17 01:27:26 PM
Re: None
Post # of 19464 
N =50 is a compromise from statistical significance to clinical significance, and even 50 is not a compelling data base for any analysis. PRO 140 IMO, will be the eighth choice on an ever revolving HAART approach. Physicians will be very reticent in adopting a N=50 drug before trying all the established HAART combinations. Habit and comfort precedes PRO 140, especially with a N=50 data base.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist